p.94 抽出テキスト

Proc Natl Acad Sci USA 2020;117:7990–8000. https://doi.org/10.1073/pnas.19148 53117 934. Lee YB, Han K, Kim B, Lee SE, Jun JE, Ahn J, et al. Risk of early mortality and cardiovascular disease in type 1 diabetes: a comparison with type 2 diabetes, a nationwide study. Cardiovasc Diabetol 2019;18:157. https://doi.org/10.1186/s12933-019-0953-7 935. Bisson A, Bodin A, Fauchier G, Herbert J, Angoulvant D, Ducluzeau PH, et al. Sex, age, type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a nationwide analysis. Cardiovasc Diabetol 2021;20:24. https://doi.org/10.1186/s12933- 021-01216-7 936. Dahlqvist S, Rosengren A, Gudbjörnsdottir S, Pivodic A, Wedel H, Kosiborod M, et al. Risk of atrial fibrillation in people with type 1 diabetes compared with matched controls from the general population: a prospective case-control study. Lancet Diabetes Endocrinol 2017;5:799–807. https://doi.org/10.1016/S2213-8587(17)30262-0 937. Cai X, Li J, Cai W, Chen C, Ma J, Xie Z, et al. Meta-analysis of type 1 diabetes mellitus and risk of cardiovascular disease. J Diabetes Complications 2021;35:107833. https://doi. org/10.1016/j.jdiacomp.2020.107833 938. Zellerhoff S, Pistulli R, Monnig G, Hinterseer M, Beckmann BM, Kobe J, et al. Atrial arrhythmias in long-QT syndrome under daily life conditions: a nested case control study. J Cardiovasc Electrophysiol 2009;20:401–7. https://doi.org/10.1111/j.1540-8167. 2008.01339.x 939. Johnson JN, Tester DJ, Perry J, Salisbury BA, Reed CR, Ackerman MJ. Prevalence of early-onset atrial fibrillation in congenital long QT syndrome. Heart Rhythm 2008;5: 704–9. https://doi.org/10.1016/j.hrthm.2008.02.007 940. Gaita F, Giustetto C, Bianchi F, Wolpert C, Schimpf R, Riccardi R, et al. Short QT syndrome: a familial cause of sudden death. Circulation 2003;108:965–70. https://doi.org/ 10.1161/01.CIR.0000085071.28695.C4 941. Borggrefe M, Wolpert C, Antzelevitch C, Veltmann C, Giustetto C, Gaita F, et al. Short QT syndrome genotype-phenotype correlations. J Electrocardiol 2005;38:75–80. https://doi.org/10.1016/j.jelectrocard.2005.06.009 942. Giustetto C, Di Monte F, Wolpert C, Borggrefe M, Schimpf R, Sbragia P, et al. Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J 2006;27:2440–7. https://doi.org/10.1093/eurheartj/ehl185 943. Bordachar P, Reuter S, Garrigue S, Cai X, Hocini M, Jais P, et al. Incidence, clinical implications and prognosis of atrial arrhythmias in Brugada syndrome. Eur Heart J 2004; 25:879–84. https://doi.org/10.1016/j.ehj.2004.01.004 944. Francis J, Antzelevitch C. Atrial fibrillation and Brugada syndrome. J Am Coll Cardiol 2008;51:1149–53. https://doi.org/10.1016/j.jacc.2007.10.062 945. Giustetto C, Schimpf R, Mazzanti A, Scrocco C, Maury P, Anttonen O, et al. Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol 2011;58:587–95. https://doi.org/10.1016/j.jacc.2011.03.038 946. Gollob MH, Redpath CJ, Roberts JD. The short QT syndrome: proposed diagnostic criteria. J Am Coll Cardiol 2011;57:802–12. https://doi.org/10.1016/j.jacc.2010.09.048 947. Kusano KF, Taniyama M, Nakamura K, Miura D, Banba K, Nagase S, et al. Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation, electrophysiology, and clinical backgrounds. J Am Coll Cardiol 2008;51:1169–75. https://doi.org/10. 1016/j.jacc.2007.10.060 948. Rodriguez-Manero M, Namdar M, Sarkozy A, Casado-Arroyo R, Ricciardi D, de Asmundis C, et al. Prevalence, clinical characteristics and management of atrial fibrillation in patients with Brugada syndrome. Am J Cardiol 2013;111:362–7. https://doi.org/ 10.1016/j.amjcard.2012.10.012 949. Choi YJ, Choi EK, Han KD, Jung JH, Park J, Lee E, et al. Temporal trends of the prevalence and incidence of atrial fibrillation and stroke among Asian patients with hypertrophic cardiomyopathy: a nationwide population-based study. Int J Cardiol 2018; 273:130–5. https://doi.org/10.1016/j.ijcard.2018.08.038 950. Hernandez-Ojeda J, Arbelo E, Borras R, Berne P, Tolosana JM, Gomez-Juanatey A, et al. Patients with Brugada syndrome and implanted cardioverter-defibrillators: longterm follow-up. J Am Coll Cardiol 2017;70:1991–2002. https://doi.org/10.1016/j.jacc. 2017.08.029 951. Klopotowski M, Kwapiszewska A, Kukula K, Jamiolkowski J, Dabrowski M, Derejko P, et al. Clinical and echocardiographic parameters as risk factors for atrial fibrillation in patients with hypertrophic cardiomyopathy. Clin Cardiol 2018;41:1336–40. https://doi. org/10.1002/clc.23050 952. Rowin EJ, Orfanos A, Estes NAM, Wang W, Link MS, Maron MS, et al. Occurrence and natural history of clinically silent episodes of atrial fibrillation in hypertrophic cardiomyopathy. Am J Cardiol 2017;119:1862–5. https://doi.org/10.1016/j.amjcard.2017.02.040 953. Sacher F, Probst V, Maury P, Babuty D, Mansourati J, Komatsu Y, et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study-part 2. Circulation 2013;128:1739–47. https://doi.org/10.1161/ CIRCULATIONAHA.113.001941 954. Siontis KC, Geske JB, Ong K, Nishimura RA, Ommen SR, Gersh BJ. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. J Am Heart Assoc 2014;3:e001002. https://doi.org/10.1161/JAHA. 114.001002 955. Sumitomo N, Sakurada H, Taniguchi K, Matsumura M, Abe O, Miyashita M, et al. Association of atrial arrhythmia and sinus node dysfunction in patients with catecholaminergic polymorphic ventricular tachycardia. Circ J 2007;71:1606–9. https://doi.org/10.1253/circj.71.1606 956. Sy RW, Gollob MH, Klein GJ, Yee R, Skanes AC, Gula LJ, et al. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2011;8:864–71. https://doi.org/10.1016/j.hrthm.2011.01.048 957. van Velzen HG, Theuns DA, Yap SC, Michels M, Schinkel AF. Incidence of devicedetected atrial fibrillation and long-term outcomes in patients with hypertrophic cardiomyopathy. Am J Cardiol 2017;119:100–5. https://doi.org/10.1016/j.amjcard.2016.08. 092 958. Bourfiss M, Te Riele AS, Mast TP, Cramer MJ, Van Der Heijden J, Van Veen TAB, et al. Influence of genotype on structural atrial abnormalities and atrial fibrillation or flutter in arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Electrophysiol 2016;27:1420–8. https://doi.org/10.1111/jce.13094 959. Camm CF, James CA, Tichnell C, Murray B, Bhonsale A, te Riele AS, et al. Prevalence of atrial arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm 2013;10:1661–8. https://doi.org/10.1016/j.hrthm.2013.08.032 960. Chu AF, Zado E, Marchlinski FE. Atrial arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and ventricular tachycardia. Am J Cardiol 2010;106:720–2. https://doi.org/10.1016/j.amjcard.2010.04.031 961. Hasselberg NE, Haland TF, Saberniak J, Brekke PH, Berge KE, Leren TP, et al. Lamin A/ C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation. Eur Heart J 2018;39:853–60. https://doi.org/10.1093/eurheartj/ehx596 962. Kumar S, Baldinger SH, Gandjbakhch E, Maury P, Sellal JM, Androulakis AF, et al. Long-term arrhythmic and nonarrhythmic outcomes of lamin A/C mutation carriers. J Am Coll Cardiol 2016;68:2299–307. https://doi.org/10.1016/j.jacc.2016.08.058 963. Mussigbrodt A, Knopp H, Efimova E, Weber A, Bertagnolli L, Hilbert S, et al. Supraventricular arrhythmias in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy associate with long-term outcome after catheter ablation of ventricular tachycardias. Europace 2018;20:1182–7. https://doi.org/10.1093/europace/ eux179 964. Pasotti M, Klersy C, Pilotto A, Marziliano N, Rapezzi C, Serio A, et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol 2008;52: 1250–60. https://doi.org/10.1016/j.jacc.2008.06.044 965. Saguner AM, Ganahl S, Kraus A, Baldinger SH, Medeiros-Domingo A, Saguner AR, et al. Clinical role of atrial arrhythmias in patients with arrhythmogenic right ventricular dysplasia. Circ J 2014;78:2854–61. https://doi.org/10.1253/circj.CJ-14-0474 966. Tonet JL, Castro-Miranda R, Iwa T, Poulain F, Frank R, Fontaine GH. Frequency of supraventricular tachyarrhythmias in arrhythmogenic right ventricular dysplasia. Am J Cardiol 1991;67:1153. https://doi.org/10.1016/0002-9149(91)90886-P 967. van Rijsingen IA, Nannenberg EA, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, et al. Gender-specific differences in major cardiac events and mortality in lamin A/C mutation carriers. Eur J Heart Fail 2013;15:376–84. https://doi.org/10.1093/eurjhf/ hfs191 968. Aras D, Tufekcioglu O, Ergun K, Ozeke O, Yildiz A, Topaloglu S, et al. Clinical features of isolated ventricular noncompaction in adults long-term clinical course, echocardiographic properties, and predictors of left ventricular failure. J Card Fail 2006;12: 726–33. https://doi.org/10.1016/j.cardfail.2006.08.002 969. Li S, Zhang C, Liu N, Bai H, Hou C, Wang J, et al. Genotype-positive status is associated with poor prognoses in patients with left ventricular noncompaction cardiomyopathy. J Am Heart Assoc 2018;7:e009910. https://doi.org/10.1161/JAHA.118.009910 970. Stollberger C, Blazek G, Winkler-Dworak M, Finsterer J. Atrial fibrillation in left ventricular noncompaction with and without neuromuscular disorders is associated with a poor prognosis. Int J Cardiol 2009;133:41–5. https://doi.org/10.1016/j.ijcard. 2007.11.099 971. Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 1999;341:1715–24. https://doi.org/10.1056/ NEJM199912023412302 972. Hong K, Bjerregaard P, Gussak I, Brugada R. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J Cardiovasc Electrophysiol 2005;16:394–6. https://doi. org/10.1046/j.1540-8167.2005.40621.x 973. Olesen MS, Yuan L, Liang B, Holst AG, Nielsen N, Nielsen JB, et al. High prevalence of long QT syndrome-associated SCN5A variants in patients with early-onset lone atrial fibrillation. Circ Cardiovasc Genet 2012;5:450–9. https://doi.org/10.1161/ CIRCGENETICS.111.962597 974. Pappone C, Radinovic A, Manguso F, Vicedomini G, Sala S, Sacco FM, et al. New-onset atrial fibrillation as first clinical manifestation of latent Brugada syndrome: prevalence and clinical significance. Eur Heart J 2009;30:2985–92. https://doi.org/10.1093/ eurheartj/ehp326 975. Peters S. Atrial arrhythmias in arrhythmogenic cardiomyopathy: at the beginning or at the end of the disease story? Circ J 2015;79:446. https://doi.org/10.1253/circj.CJ-14- 1193 976. Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, et al. Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy. Circulation 2017;136:2420–36. https://doi.org/10.1161/CIRCULATIONAHA.117.029267

ESC Guidelines                                                                                                                                                                                          3407

Downloaded from academic.oup.com/eurheartj/article/45/36/3314/7738779 by guest on 07 October 2026